Study of Janus Kinase 2 Levels in Men With Androgenetic Alopecia and Effects of Topical Minoxidil 5% Treatment

What this Trial Is About

Researchers are studying androgenetic alopecia, a common form of progressive hair loss affecting adult males aged 18 to 50 years. This prospective single-arm interventional study aims to compare tissue levels of Janus Kinase 2 JAK2 protein in balding versus non-balding scalp areas at the start and to evaluate changes in JAK2 expression in the balding scalp after 3 months of treatment with topical minoxidil 5%. The study also assesses clinical response through standardized trichoscopic hair evaluations. Participants will receive topical minoxidil 5% solution applied to the scalp for 12 weeks, with men applying 1 cc twice daily. At the beginning, clinical exams, photography, and trichoscopic assessments will be conducted. Three 2 mm scalp punch biopsies will be collected one from the balding area and one from the non-balding area at baseline, and another from the balding area after treatment. JAK2 protein levels will be measured by ELISA from these tissue samples. During the study, participants will undergo multiple clinical and trichoscopic evaluations and biopsies to monitor changes in hair parameters and JAK2 levels. Researchers will observe differences in JAK2 protein between balding and non-balding scalp at baseline and changes after minoxidil treatment. The study includes safety monitoring and will last for at least 12 weeks of treatment with follow-up assessments.

JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil